D
Avid Bioservices, Inc.
CDMO
$8.25
$0.050.61%
D
Sell
11/1/2023Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to D from D+ on 11/1/2023 due to a large decline in the total return index, volatility index and efficiency index. Net income declined 577.35% from -$309 to -$2.09M.
Avid Bioservices, Inc. (CDMO) was downgraded to D from D+ on 11/1/2023 due to a large decline in the total return index, volatility index and efficiency index. Net income declined 577.35% from -$309 to -$2.09M.
D
Sell
6/23/2023Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to D+ from C- on 6/23/2023 due to a large decline in the total return index.
Avid Bioservices, Inc. (CDMO) was downgraded to D+ from C- on 6/23/2023 due to a large decline in the total return index.
C
Hold
6/22/2023Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C+ on 6/22/2023 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 167.03% from $461 to -$309, earnings per share declined from $0.0074 to -$0.0049, and EBIT declined 65.71% from $2.72M to $932.
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C+ on 6/22/2023 due to a significant decline in the valuation index, growth index and efficiency index. Net income declined 167.03% from $461 to -$309, earnings per share declined from $0.0074 to -$0.0049, and EBIT declined 65.71% from $2.72M to $932.
C
Hold
6/6/2023Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C+ from C on 6/6/2023 due to a major increase in the total return index and valuation index.
Avid Bioservices, Inc. (CDMO) was upgraded to C+ from C on 6/6/2023 due to a major increase in the total return index and valuation index.
C
Hold
5/22/2023Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C from C+ on 5/22/2023 due to a decline in the total return index, valuation index and growth index.
Avid Bioservices, Inc. (CDMO) was downgraded to C from C+ on 5/22/2023 due to a decline in the total return index, valuation index and growth index.
C
Hold
3/14/2023Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C+ from C on 3/14/2023 due to a significant increase in the growth index, efficiency index and volatility index. EBIT increased 201.27% from -$2.68M to $2.72M, net income increased 139.88% from -$1.16M to $461, and earnings per share increased from -$0.02 to $0.0074.
Avid Bioservices, Inc. (CDMO) was upgraded to C+ from C on 3/14/2023 due to a significant increase in the growth index, efficiency index and volatility index. EBIT increased 201.27% from -$2.68M to $2.72M, net income increased 139.88% from -$1.16M to $461, and earnings per share increased from -$0.02 to $0.0074.
C
Hold
12/7/2022Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C from C+ on 12/7/2022 due to a major decline in the growth index, solvency index and total return index. Earnings per share declined from $0.02 to -$0.02, EBIT declined 198.14% from $2.74M to -$2.68M, and the quick ratio declined from 1.59 to 1.27.
Avid Bioservices, Inc. (CDMO) was downgraded to C from C+ on 12/7/2022 due to a major decline in the growth index, solvency index and total return index. Earnings per share declined from $0.02 to -$0.02, EBIT declined 198.14% from $2.74M to -$2.68M, and the quick ratio declined from 1.59 to 1.27.
C
Hold
7/5/2022Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C+ from C on 7/5/2022 due to an increase in the total return index.
Avid Bioservices, Inc. (CDMO) was upgraded to C+ from C on 7/5/2022 due to an increase in the total return index.
C
Hold
6/30/2022Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 6/30/2022 due to a significant increase in the valuation index, solvency index and efficiency index. Net income increased 5,042.26% from $2.25M to $115.6M, debt to equity declined from 2.52 to 0.82, and total capital increased 49.03% from $239.92M to $357.56M.
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 6/30/2022 due to a significant increase in the valuation index, solvency index and efficiency index. Net income increased 5,042.26% from $2.25M to $115.6M, debt to equity declined from 2.52 to 0.82, and total capital increased 49.03% from $239.92M to $357.56M.
C
Hold
6/3/2022Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 6/3/2022 due to a decline in the total return index and volatility index.
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 6/3/2022 due to a decline in the total return index and volatility index.
C
Hold
3/15/2022Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 3/15/2022 due to an increase in the efficiency index, valuation index and growth index. Total revenue increased 20.68% from $26.11M to $31.51M, and total capital increased 2.54% from $233.97M to $239.92M.
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 3/15/2022 due to an increase in the efficiency index, valuation index and growth index. Total revenue increased 20.68% from $26.11M to $31.51M, and total capital increased 2.54% from $233.97M to $239.92M.
C
Hold
2/16/2022Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 2/16/2022 due to a decline in the total return index, volatility index and valuation index.
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 2/16/2022 due to a decline in the total return index, volatility index and valuation index.
C
Hold
1/27/2022Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 1/27/2022 due to an increase in the total return index and valuation index.
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 1/27/2022 due to an increase in the total return index and valuation index.
C
Hold
1/12/2022Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 1/12/2022 due to a significant decline in the total return index.
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 1/12/2022 due to a significant decline in the total return index.
C
Hold
12/9/2021Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C from C+ on 12/9/2021 due to a major decline in the growth index. Earnings per share declined from $0.1 to $0.0573, EBIT declined 40.08% from $6.93M to $4.15M, and total revenue declined 15.1% from $30.75M to $26.11M.
Avid Bioservices, Inc. (CDMO) was downgraded to C from C+ on 12/9/2021 due to a major decline in the growth index. Earnings per share declined from $0.1 to $0.0573, EBIT declined 40.08% from $6.93M to $4.15M, and total revenue declined 15.1% from $30.75M to $26.11M.
C
Hold
11/3/2021Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C+ from C on 11/3/2021 due to a significant increase in the total return index and solvency index.
Avid Bioservices, Inc. (CDMO) was upgraded to C+ from C on 11/3/2021 due to a significant increase in the total return index and solvency index.
C
Hold
9/24/2021Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C from C+ on 9/24/2021 due to a significant decline in the total return index and volatility index.
Avid Bioservices, Inc. (CDMO) was downgraded to C from C+ on 9/24/2021 due to a significant decline in the total return index and volatility index.
C
Hold
9/9/2021Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C+ from C- on 9/9/2021 due to a significant increase in the growth index, total return index and efficiency index. Earnings per share increased from -$0.0377 to $0.1, net income increased 216.62% from $1.99M to $6.3M, and EBIT increased 124.45% from $3.09M to $6.93M.
Avid Bioservices, Inc. (CDMO) was upgraded to C+ from C- on 9/9/2021 due to a significant increase in the growth index, total return index and efficiency index. Earnings per share increased from -$0.0377 to $0.1, net income increased 216.62% from $1.99M to $6.3M, and EBIT increased 124.45% from $3.09M to $6.93M.
C
Hold
7/1/2021Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 7/1/2021 due to a major decline in the growth index and valuation index. Earnings per share declined from $0.01 to -$0.0377.
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 7/1/2021 due to a major decline in the growth index and valuation index. Earnings per share declined from $0.01 to -$0.0377.
C
Hold
1/25/2021Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 1/25/2021 due to an increase in the total return index and volatility index.
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 1/25/2021 due to an increase in the total return index and volatility index.
C
Hold
12/3/2020Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 12/3/2020 due to a large decline in the growth index and solvency index. Earnings per share declined from $0.0582 to $0.01, EBIT declined 52.28% from $4.72M to $2.25M, and total revenue declined 17.04% from $25.39M to $21.06M.
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 12/3/2020 due to a large decline in the growth index and solvency index. Earnings per share declined from $0.0582 to $0.01, EBIT declined 52.28% from $4.72M to $2.25M, and total revenue declined 17.04% from $25.39M to $21.06M.
C
Hold
11/18/2020Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 11/18/2020 due to a noticeable increase in the total return index and volatility index.
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 11/18/2020 due to a noticeable increase in the total return index and volatility index.
C
Hold
11/3/2020Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 11/3/2020 due to a decline in the total return index.
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 11/3/2020 due to a decline in the total return index.
C
Hold
10/16/2020Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 10/16/2020 due to an increase in the total return index and volatility index.
Avid Bioservices, Inc. (CDMO) was upgraded to C from C- on 10/16/2020 due to an increase in the total return index and volatility index.
C
Hold
9/21/2020Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 9/21/2020 due to a noticeable decline in the total return index.
Avid Bioservices, Inc. (CDMO) was downgraded to C- from C on 9/21/2020 due to a noticeable decline in the total return index.
C
Hold
9/3/2020Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C from D+ on 9/3/2020 due to a significant increase in the growth index, efficiency index and solvency index. Net income increased 199.2% from -$4.77M to $4.73M, EBIT increased 197.76% from -$4.83M to $4.72M, and earnings per share increased from -$0.1036 to $0.0582.
Avid Bioservices, Inc. (CDMO) was upgraded to C from D+ on 9/3/2020 due to a significant increase in the growth index, efficiency index and solvency index. Net income increased 199.2% from -$4.77M to $4.73M, EBIT increased 197.76% from -$4.83M to $4.72M, and earnings per share increased from -$0.1036 to $0.0582.
D
Sell
8/25/2020Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to D+ from D on 8/25/2020 due to a large increase in the total return index.
Avid Bioservices, Inc. (CDMO) was upgraded to D+ from D on 8/25/2020 due to a large increase in the total return index.
D
Sell
8/7/2020Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to D from D+ on 8/7/2020 due to a decline in the total return index and valuation index.
Avid Bioservices, Inc. (CDMO) was downgraded to D from D+ on 8/7/2020 due to a decline in the total return index and valuation index.
D
Sell
7/16/2020Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to D+ from D on 7/16/2020 due to an increase in the efficiency index and total return index.
Avid Bioservices, Inc. (CDMO) was upgraded to D+ from D on 7/16/2020 due to an increase in the efficiency index and total return index.
D
Sell
4/7/2020Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to D from D+ on 4/7/2020 due to a noticeable decline in the total return index and volatility index.
Avid Bioservices, Inc. (CDMO) was downgraded to D from D+ on 4/7/2020 due to a noticeable decline in the total return index and volatility index.
D
Sell
3/11/2020Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to D+ from C- on 3/11/2020 due to a significant decline in the growth index, efficiency index and solvency index. EBIT declined 1,170.69% from -$174 to -$2.21M, net income declined 389.3% from -$430 to -$2.1M, and operating cash flow declined 110.81% from $5.88M to -$636.
Avid Bioservices, Inc. (CDMO) was downgraded to D+ from C- on 3/11/2020 due to a significant decline in the growth index, efficiency index and solvency index. EBIT declined 1,170.69% from -$174 to -$2.21M, net income declined 389.3% from -$430 to -$2.1M, and operating cash flow declined 110.81% from $5.88M to -$636.
C
Hold
1/14/2020Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C- from D+ on 1/14/2020 due to an increase in the total return index, solvency index and volatility index.
Avid Bioservices, Inc. (CDMO) was upgraded to C- from D+ on 1/14/2020 due to an increase in the total return index, solvency index and volatility index.
D
Sell
12/10/2019Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to D+ from D on 12/10/2019 due to a major increase in the growth index and volatility index. Operating cash flow increased 338.41% from -$2.47M to $5.88M, EBIT increased 94.84% from -$3.37M to -$174, and earnings per share increased from -$0.082 to -$0.0333.
Avid Bioservices, Inc. (CDMO) was upgraded to D+ from D on 12/10/2019 due to a major increase in the growth index and volatility index. Operating cash flow increased 338.41% from -$2.47M to $5.88M, EBIT increased 94.84% from -$3.37M to -$174, and earnings per share increased from -$0.082 to -$0.0333.
D
Sell
10/21/2019Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to D from D+ on 10/21/2019 due to a substantial decline in the total return index.
Avid Bioservices, Inc. (CDMO) was downgraded to D from D+ on 10/21/2019 due to a substantial decline in the total return index.
D
Sell
9/23/2019Downgrade
Avid Bioservices, Inc. (CDMO) was downgraded to D+ from C- on 9/23/2019 due to a substantial decline in the growth index, efficiency index and solvency index. EBIT declined 4,597.33% from $75 to -$3.37M, net income declined 1,041.67% from $336 to -$3.16M, and earnings per share declined from -$0.0133 to -$0.082.
Avid Bioservices, Inc. (CDMO) was downgraded to D+ from C- on 9/23/2019 due to a substantial decline in the growth index, efficiency index and solvency index. EBIT declined 4,597.33% from $75 to -$3.37M, net income declined 1,041.67% from $336 to -$3.16M, and earnings per share declined from -$0.0133 to -$0.082.
C
Hold
5/2/2019Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to C- from D+ on 5/2/2019 due to an increase in the total return index, growth index and volatility index.
Avid Bioservices, Inc. (CDMO) was upgraded to C- from D+ on 5/2/2019 due to an increase in the total return index, growth index and volatility index.
D
Sell
3/12/2019Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to D+ from D on 3/12/2019 due to a substantial increase in the growth index, efficiency index and valuation index. Operating cash flow increased 54.09% from -$6.71M to -$3.08M, EBIT increased 51.97% from -$2.48M to -$1.19M, and total revenue increased 35.4% from $10.18M to $13.78M.
Avid Bioservices, Inc. (CDMO) was upgraded to D+ from D on 3/12/2019 due to a substantial increase in the growth index, efficiency index and valuation index. Operating cash flow increased 54.09% from -$6.71M to -$3.08M, EBIT increased 51.97% from -$2.48M to -$1.19M, and total revenue increased 35.4% from $10.18M to $13.78M.
D
Sell
12/11/2018Upgraded
Avid Bioservices, Inc. (CDMO) was upgraded to D from D- on 12/11/2018 due to an increase in the solvency index, volatility index and efficiency index. Net income increased 26.01% from -$1.96M to -$1.45M, and the quick ratio increased from 1.76 to 1.81.
Avid Bioservices, Inc. (CDMO) was upgraded to D from D- on 12/11/2018 due to an increase in the solvency index, volatility index and efficiency index. Net income increased 26.01% from -$1.96M to -$1.45M, and the quick ratio increased from 1.76 to 1.81.
D
Sell
12/13/2017Downgrade
Peregrine Pharmaceuticals, Inc. (PPHM) was downgraded to D- from D on 12/13/2017 due to a large decline in the growth index, valuation index and efficiency index. Net income declined 947.63% from -$1.21M to -$12.62M, earnings per share declined from -$0.0591 to -$0.3119, and EBIT declined 304.87% from -$2.73M to -$11.05M.
Peregrine Pharmaceuticals, Inc. (PPHM) was downgraded to D- from D on 12/13/2017 due to a large decline in the growth index, valuation index and efficiency index. Net income declined 947.63% from -$1.21M to -$12.62M, earnings per share declined from -$0.0591 to -$0.3119, and EBIT declined 304.87% from -$2.73M to -$11.05M.
D
Sell
9/14/2017Upgraded
Peregrine Pharmaceuticals, Inc. (PPHM) was upgraded to D from D- on 9/14/2017 due to a major increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.1508 to -$0.0591, total revenue increased 51.23% from $17.9M to $27.08M, and EBIT increased 48.55% from -$5.3M to -$2.73M.
Peregrine Pharmaceuticals, Inc. (PPHM) was upgraded to D from D- on 9/14/2017 due to a major increase in the total return index, growth index and volatility index. Earnings per share increased from -$0.1508 to -$0.0591, total revenue increased 51.23% from $17.9M to $27.08M, and EBIT increased 48.55% from -$5.3M to -$2.73M.
D
Sell
2/17/2017Upgraded
Peregrine Pharmaceuticals, Inc. (PPHM) was upgraded to D- from E+ on 2/17/2017 due to an increase in the total return index and volatility index.
Peregrine Pharmaceuticals, Inc. (PPHM) was upgraded to D- from E+ on 2/17/2017 due to an increase in the total return index and volatility index.
E
Sell
1/30/2017Downgrade
Peregrine Pharmaceuticals, Inc. (PPHM) was downgraded to E+ from D- on 1/30/2017 due to a decline in the solvency index, total return index and volatility index.
Peregrine Pharmaceuticals, Inc. (PPHM) was downgraded to E+ from D- on 1/30/2017 due to a decline in the solvency index, total return index and volatility index.
D
Sell
3/11/2016Downgrade
Peregrine Pharmaceuticals, Inc. (PPHM) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Total revenue declined 29.55% from $9.52M to $6.71M, EBIT declined 22.01% from -$13.82M to -$16.87M, and earnings per share declined from -$0.0715 to -$0.0802.
Peregrine Pharmaceuticals, Inc. (PPHM) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and growth index. Total revenue declined 29.55% from $9.52M to $6.71M, EBIT declined 22.01% from -$13.82M to -$16.87M, and earnings per share declined from -$0.0715 to -$0.0802.
NASDAQ
05/03/2024 4:00PM Eastern
Quotes delayed
